Metallothionein-2A licenses an S100A8 alarmin program to drive epithelial-mesenchymal transition in pulmonary fibrosis
BackgroundPulmonary fibrosis (PF) is a progressive interstitial lung disease driven in part by epithelial–mesenchymal transition (EMT), but the upstream epithelial regulators remain undefined, and conventional screens rarely separate causal drivers fro…